SL
Silexion Therapeutics Ltd.
SLXN · NASDAQ
$0.26 -6.85% (-$0.02)
1M -26.08%
Market Cap $116.9K
P/E Ratio -
Div. Yield -
ROE 276.59%
Bulios Fair Price
$0.36
38.5% upside
Current Price
$0.26
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SLXN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
72 /100
Cheap P/B 2.66x
EV/EBITDA N/A
P/S N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
40 /100
Average ROE 276.59%
ROA 161.47%
Asset turnover 0.00x
Debt
8 /100
High Current ratio 0.94x
Int. coverage -2,346.83x
Debt/Equity 32.05x
Stability
19 /100
Unstable EPS volatility 7,313.59%
Profitable years 0
Beta -0.25x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SLXN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Ilan Hadar
Employees
14
Headquarters
Jerusalem
Upcoming events
11 NOV
Earnings
Upcoming earnings report